PHARMACEUTICAL COMPOSITION COMPRISING ACTIVATION T CELLS SPECIFIC TO K-RAS FOR PREVENTING AND TREATING LUNG ADENOCARCINOMA AND PREPARATION METHOD THEREFOR
A pharmaceutical composition comprising activation T cells specific to K-ras for preventing and treating lung adenocarcinoma, according to the present invention, uses, as an antigen composition, a K-ras mutant (G12D, G12V, and G13D) recombinant overlapping peptide, which is designed such that a total of 12 epitopes (n= 1 to 12, and the last epitope (n=12) consists of 23 amino acids) in units of 30 amino acids sequentially in the amino acid sequence of K-ras are distinguished, and the sequence of 15 amino acids overlaps between epitopes. Accordingly, there are advantages of being more effective in recognizing and killing lung adenocarcinoma in which K-ras, K-ras mutant G12V, K-ras mutant G12D, or K-ras mutant G13D is detected. Therefore, when the pharmaceutical composition according to the present invention comprising activation T cells specific to K-ras for preventing and treating lung adenocarcinoma is used, there are advantages of being able to effectively prevent and treat lung adenocarcinoma, specifically, lung large cell adenocarcinoma, in which K-ras and K-ras mutants are detected..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 06. Juli Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LEE WANG JUN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-07-06, Last update posted on www.tib.eu: 2023-08-08, Last updated: 2023-08-11 |
|---|
| Patentnummer: |
WO2023128380 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA017656958 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA017656958 | ||
| 003 | DE-627 | ||
| 005 | 20230811085338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230721s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA017656958 | ||
| 035 | |a (EPA)WO2023128380 | ||
| 035 | |a (EPA)86999552 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LEE WANG JUN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PHARMACEUTICAL COMPOSITION COMPRISING ACTIVATION T CELLS SPECIFIC TO K-RAS FOR PREVENTING AND TREATING LUNG ADENOCARCINOMA AND PREPARATION METHOD THEREFOR |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-07-06, Last update posted on www.tib.eu: 2023-08-08, Last updated: 2023-08-11 | ||
| 520 | |a A pharmaceutical composition comprising activation T cells specific to K-ras for preventing and treating lung adenocarcinoma, according to the present invention, uses, as an antigen composition, a K-ras mutant (G12D, G12V, and G13D) recombinant overlapping peptide, which is designed such that a total of 12 epitopes (n= 1 to 12, and the last epitope (n=12) consists of 23 amino acids) in units of 30 amino acids sequentially in the amino acid sequence of K-ras are distinguished, and the sequence of 15 amino acids overlaps between epitopes. Accordingly, there are advantages of being more effective in recognizing and killing lung adenocarcinoma in which K-ras, K-ras mutant G12V, K-ras mutant G12D, or K-ras mutant G13D is detected. Therefore, when the pharmaceutical composition according to the present invention comprising activation T cells specific to K-ras for preventing and treating lung adenocarcinoma is used, there are advantages of being able to effectively prevent and treat lung adenocarcinoma, specifically, lung large cell adenocarcinoma, in which K-ras and K-ras mutants are detected. | ||
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a MOON HYOUN JONG |4 aut | |
| 700 | 0 | |a LIM SUN KI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 06. Juli |
| 773 | 1 | 8 | |g year:2023 |g day:06 |g month:07 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/86999552/publication/WO2023128380A1?q=WO2023128380 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 06 |c 07 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 06 |c 07 | ||